Physician profile
Nahndi Bush
NPI 1568504280
$24,256.78
in general payments reported to CMS, 2019-2025
32 companies · $4,044 in 2025
The $4,044 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,036 · 2020: $1,728 · 2021: $2,035 · 2022: $4,700 · 2023: $4,009 · 2024: $3,706 · 2025: $4,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,758.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $5,221.51 | 2019-2025 | Idose, Idosetr, Istent |
| Johnson & Johnson Surgical Vision, INC. | $2,454.64 | 2019-2024 | Tecnis Iol, Tecnis Iol, Catalys System |
| Alcon Vision LLC | $2,254.97 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Abbvie INC. | $2,101.52 | 2022-2025 | Durysta, Vuity, Xen Glaucoma Treatment System |
| Sight Sciences, INC. | $1,905.55 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Allergan, INC. | $1,824.85 | 2019-2022 | |
| New World Medical,INC. | $1,641.05 | 2019-2025 | Kahook Dual Blade, Streamline, Clearpath |
| Bausch & Lomb Americas INC. | $1,309.67 | 2022-2025 | Vyzulta, Miebo, Envista Mx60 Iol |
| Aerie Pharmaceuticals, INC. | $774.35 | 2019-2021 | |
| Ivantis, INC | $610.21 | 2019-2021 | |
| Oyster Point Pharma, INC. | $442.30 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $433.61 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $381.87 | 2019-2025 | Cequa |
| Dompe US, INC. | $336.72 | 2023-2025 | Oxervate |
| Biotissue Holdings INC. | $332.39 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $272.33 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.06 | 2019-2021 | |
| Rxsight INC | $248.32 | 2025 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Ocular Therapeutix, INC. | $198.50 | 2021-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $161.79 | 2025 | Xdemvy |
| Harrow Eye, LLC | $154.67 | 2024 | Vevye |
| Astellas Pharma US INC | $135.42 | 2024 | Izervay |
| Lumenis Be INC | $133.71 | 2022 | |
| Rayner Intraocular Lenses Limited | $124.75 | 2024 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Kala Pharmaceuticals, INC. | $118.62 | 2021 | |
| Amgen INC. | $97.62 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $94.96 | 2023 | Tepezza |
| Pfizer INC. | $69.38 | 2024 | |
| Novartis Pharmaceuticals Corporation | $68.91 | 2019-2022 | |
| Shire North American Group INC | $42.10 | 2019 | |
| Omeros Corporation | $30.00 | 2019 | |
| Travere Therapeutics, INC. | $15.43 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nahndi Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.